#### Stefan's Neuroimaging Section

- 80 Revision Questions

### Jacqueline's Neural Basis of Memory Section

- 60 Revision Questions

## Olivia's Neuropharmacology Section

- 90 Revision Questions

#### Patrick's Genetic's Section

- 70 Revision Questions

## **TMS Methods and Research**

- 1. How is TMS applied?
- 2. What occurs at the neuronal level during TMS application?
- 3. What role did Barker, Jalinous and Freestone play in TMS imaging?
- 4. Why use of a 'figure-eight' coil?
- 5. What does TMS 'neural noise approach' achieve'?
- 6. How did Amassian's study (1989) employ the 'neural noise approach' and what were implications of findings/conclusions?
- 7. How did Amassian's study (1993) employ the 'neural noise approach' and what were implications of findings/conclusions?
- 8. How did Fitzgerald et al.'s study (2003) employ the 'paired pulse approach' and what were implications of findings/conclusions?
- 9. What does 'virtual lesion' (r) TMS approach' achieve'?
- 10. What does TMS 'probing excitability approach' achieve'?
- 11. What are 'motor-evoked potentials' (MEPs)?
- 12. What were the findings/conclusions of Eisenegger et al. (2007) TMS Study?
- 13. What were the findings/conclusions of Bode et al. (2007) TMS Study?
- 14. What does TMS 'paired pulse approach' achieve'?

### 15. Outline an example of clinical application of TMS

## **Alzheimer's Disease**

- 1. Describe aetiology of Alzheimer's' Disease (AD)
- 2. What is the prevalence of AD?
- 3. What are the clinical features of phase one AD?
- 4. What are the clinical features of phase two AD?
- 5. What are the clinical features of phase three AD?
- 6. Describe pathological features of the AD brain
- 7. What are 'senile plaques' and neurofibrillary' tangles?
- 8. Describe the course of neuropathological changes
- 9. What is McKhann et al.'s criteria for 'probable AD'?
- 10. What is McKhann et al.'s criteria for 'possible AD'?
- 11. What is McKhann et al.'s criteria for 'definite AD'?
- 12. Describe the pattern of amnestic presentations of cognitive impairment
- 13. Treatment for AD?
- 14. What differentiates AD from normal aging?
- 15. What features did MK exhibit in her follow-up assessment that led to an AD diagnosis?

# **Introduction to Psychopharmacology**

- 1. Outline 'Iron Channel' receptor and sequence
- 2. Outline 'G-protein coupled' receptor and sequence
- 3. What does 'receptor specificity' refer to?
- 4. Outline 'action-potential' process?
- 5. What differentiates 'neurotransmitters' and 'neuromodulators'?
- 6. How may neurotransmission be understood as 'currency'?